[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647007":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":60,"collaborators":24,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":24,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":88,"whyStopped":24,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Mississippi Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Any patient with confirmed Sickle Cell Disease in pain crisis.","EXPERIMENTAL","This group will be any patient, aged 2 years until 21 years with confirmed sickle cell disease who presents to the Pediatric Emergency Department with Pain will receive multimodal pain control using Acetaminophen, Toradol, lidocaine patch, and heat packs, as well as IV Ketamine in place of Opioids.",[13],"Drug: Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses.",{"label":15,"type":6,"description":15,"interventionNames":16},"Retrospective Historical Control Group",[17],"Other: Standard Care (in control arm)",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses.","This dosing is based off of Ideal body weight of each patient and dosed at 0.3 mg\u002Fkg\u002Fdose.",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Standard Care (in control arm)","Standard Care in Historical Control Group",[15],[30],{"name":31,"affiliation":5,"role":32},"John N Freeman, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Cynthia Karlson, Ph.D.","CONTACT","601-984-2723","ckarlson@umc.edu",[40],{"facility":41,"status":24,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"University of Mississippi Medical Center, Pediatric Emergency Department","Jackson","Mississippi","39216","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-90.18481,32.29876,{"lat":51,"lon":50},[54,55,58],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},{"name":56,"role":57,"phone":24,"phoneExt":24,"email":24},"Elizabeth Adeyemi, MD","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":24,"phoneExt":24,"email":24},"Laci M Edwards, MD",{"type":32,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Cynthia Karlson","Professor, Vice-Chair for Pediatric Research","100647007","phase-4-low-dose-bolus-ketamine-for-use-in-sickle-cell-pain-crisis-100647007",false,"NCT07682662","Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis","Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain","Inclusion Criteria:\n\n* Confirmed Sickle Cell Disease (any genotype), Presenting to the Emergency Department with Vaso-occlusive crisis\u002Fpain crisis, Consent obtained\n\nExclusion Criteria:\n\n* Ketamine allergy, Severe agitation\u002Fpsychosis, Pregnancy, Hemodynamic instability (as judged by physician), Increased intracranial pressure, Severe hepatic impairment, Ketamine use within the previous 24 hours, Presentation for non-VOC-related pain (i.e. fever, acute chest syndrome, stroke, traumatic injuries etc).","ALL","2 Years","21 Years",{"count":74,"type":75},400,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are:\n\nDoes Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis.\n\nDoes Ketamine decrease the amount of time it takes to reach adequate pain control\u002Fpain score improvement, as compared to Opioids.\n\nPatients could have too low or too high blood pressure or sleepiness. Researchers will compare Ketamine to Opioids (Morphine or Dilaudid) to see if Ketamine works to treat pain enough that you do not need to be admitted to the hospital.\n\nParticipants will:\n\nOn arrival to the Children's ER for Sickle Cell Pain crisis will get Ketamine, instead of Morphine or Dilaudid, along with the typical Tylenol, Toradol, Lidocaine patch for pain control while in the ER.\n\nDuring this time we will follow your reported pain scale (0-10) to monitor your pain response to the Ketamine, as well as follow rate of hospital admission.",[81,82],"Vaso-Occlusive Pain Episode in Sickle Cell Disease","Sickle Cell Disease (SCD)",[84,85,86,87],"Pain dosed ketamine","pediatric sickle cell pain crisis","Ketamine in sickle cell pain","sickle cell pain","NOT_YET_RECRUITING","2026-06-26",{"date":91,"type":92},"2026-07-06","ACTUAL",{"date":94,"type":75},"2026-08-01",{"date":96,"type":75},"2029-10-01",{"name":5,"class":6},1]